Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4—12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3—9 months; 3) CI against the background of CCI at a dose of 500—2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson’s disease at a dose of 1000 mg/day 12—18 months.
O. A. Shavlovskaya (2026) studied this question.